Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study

被引：25

作者：

Duan, Xuhua ^{[1
]}

Li, Hao ^{[1
]}

Kuang, Donglin ^{[1
]}

Chen, Pengfei ^{[1
]}

Zhang, Kai ^{[2
]}

Li, Yanliang ^{[3
]}

He, Xiang ^{[4
]}

Xing, Cheng ^{[5
]}

Wang, Haibo ^{[6
]}

Liu, Yaoxian ^{[7
]}

Xie, Limin ^{[8
]}

Zhang, Shixi ^{[9
]}

Zhang, Qiang ^{[10
]}

Zhu, Peixin ^{[11
]}

Dong, Honglin ^{[12
]}

Xie, Jichen ^{[13
]}

Li, Hui ^{[14
]}

Wang, Yong ^{[15
]}

Shi, Ming ^{[16
]}

Jiang, Guangbin ^{[17
]}

Xu, Yandong ^{[18
]}

Zhou, Shiqi ^{[19
]}

Shang, Chunyu ^{[20
]}

Ren, Jianzhuang ^{[1
]}

Han, Xinwei ^{[1
]}

机构：

[1] Zhengzhou Univ, Affiliated Hosp 1, Dept Intervent Radiol, 1, East Jian She Rd, Zhengzhou, Henan, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 3, Dept Intervent Radiol, Zhengzhou, Henan, Peoples R China

[3] Dengzhou Peoples Hosp, Dept Intervent & Oncol, Nanyang, Henan, Peoples R China

[4] Henan Univ, Huaihe Hosp, Dept Med Imaging, Kaifeng, Henan, Peoples R China

[5] Zhoukou Cent Hosp, Dept Intervent Radiol, Zhoukou, Henan, Peoples R China

[6] Zhengzhou Cent Hosp, Dept Intervent Radiol, Zhengzhou, Henan, Peoples R China

[7] Luohe Cent Hosp, Dept Intervent Radiol, Luohe, Henan, Peoples R China

[8] Shangqiu First Peoples Hosp, Dept Intervent Radiol, Shangqiu, Henan, Peoples R China

[9] Shangqiu Municipal Hosp, Dept Infect, Shangqiu, Henan, Peoples R China

[10] Anyang Dist Hosp, Dept Intervent Radiol, Anyang, Henan, Peoples R China

[11] Gen Hosp Pingmei Shenma Grp, Dept Intervent Radiol, Pingdingshan, Henan, Peoples R China

[12] Peoples Hosp Anyang City, Dept Intervent Radiol, Anyang, Henan, Peoples R China

[13] Fifth Peoples Hosp Puyang City, Dept Intervent Radiol, Puyang, Henan, Peoples R China

[14] Peoples Hosp Jiaozuo City, Dept Intervent Radiol, Jiaozuo, Henan, Peoples R China

[15] Hainan Med Univ, Affiliated Hosp 2, Dept Intervent Vasc Surg, Haikou, Hainan, Peoples R China

[16] Second Hosp Xingtai, Dept Radiol, Xingtai, Hebei, Peoples R China

[17] Suizhou Cent Hosp, Dept Intervent Radiol, Suizhou, Hubei, Peoples R China

[18] Erdos Cent Hosp, Dept CT MRI, Erdos, Inner Mongolia, Peoples R China

[19] North China Univ Sci, Technol Affiliated Hosp, Dept Intervent Radiol, Tangshan, Hebei, Peoples R China

[20] Siping Cent Peoples Hosp, Dept Intervent Radiol, Siping, Jilin, Peoples R China

来源：

HEPATOLOGY INTERNATIONAL | 2023年 / 17卷 / 04期

基金：

中国国家自然科学基金;

关键词：

Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Apatinib; Camrelizumab; TRANSARTERIAL CHEMOEMBOLIZATION; THERAPIES; SAFETY;

D O I：

10.1007/s12072-023-10519-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

BackgroundThe evidence of transcatheter arterial chemoembolization (TACE) plus tyrosine kinase inhibitor and immune checkpoint inhibitor in unresectable hepatocellular carcinoma (HCC) was limited. This study aimed to evaluate the role of TACE plus apatinib (TACE + A) and TACE combined with apatinib plus camrelizumab (TACE + AC) in patients with unresectable HCC.MethodsThis study retrospectively reviewed patients with unresectable HCC who received TACE + A or TACE + AC in 20 centers of China from January 1, 2019 to June 31, 2021. Propensity score matching (PSM) at 1:1 was performed to reduce bias. Treatment-related adverse events (TRAEs), overall survival (OS), progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) were collected.ResultsA total of 960 eligible patients with HCC were included in the final analysis. After PSM, there were 449 patients in each group, and the baseline characteristics were balanced between two groups. At data cutoff, the median follow-up time was 16.3 (range: 11.9-21.4) months. After PSM, the TACE + AC group showed longer median OS (24.5 vs 18.0 months, p < 0.001) and PFS (10.8 vs 7.7 months, p < 0.001) than the TACE + A group; the ORR (49.9% vs 42.5%, p = 0.002) and DCR (88.4% vs 84.0%, p = 0.003) of the TACE + AC group were also higher than those in the TACE + A group. Fever, pain, hypertension and hand-foot syndrome were the more common TRAEs in two groups.ConclusionsBoth TACE plus apatinib and TACE combined with apatinib plus camrelizumab were feasible in patients with unresectable HCC, with manageable safety profiles. Moreover, TACE combined with apatinib plus camrelizumab showed additional benefit.

引用

页码：915 / 926

页数：12

共 37 条

[1] Transarterial Chemoembolization Combined With Lenvatinib Plus PD-1 Inhibitor for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study [J].

Cai, Mingyue ;

Huang, Wensou ;

Huang, Jingjun ;

Shi, Wenbo ;

Guo, Yongjian ;

Liang, Licong ;

Zhou, Jingwen ;

Lin, Liteng ;

Cao, Bihui ;

Chen, Ye ;

Zhou, Juan ;

Zhu, Kangshun .

FRONTIERS IN IMMUNOLOGY, 2022, 13

[2] EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018) [J].

Galle, Peter R. ;

Forner, Alejandro ;

Llovet, Josep M. ;

Mazzaferro, Vincenzo ;

Piscaglia, Fabio ;

Raoul, Jean-Luc ;

Schirmacher, Peter ;

Vilgrain, Valerie .

JOURNAL OF HEPATOLOGY, 2019, 70 (04) :817-817

[3]

Expert Committee on Safety Management of Antitumor Drugs

[4]

Expert Committee on Immunotherapy C.S.C.O, 2020, MILITARY MED RES, V25, P840

[5] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma [J].

Finn, Richard S. ;

Qin, Shukui ;

Ikeda, Masafumi ;

Galle, Peter R. ;

Ducreux, Michel ;

Kim, Tae-You ;

Kudo, Masatoshi ;

Breder, Valeriy ;

Merle, Philippe ;

Kaseb, Ahmed O. ;

Li, Daneng ;

Verret, Wendy ;

Xu, Derek-Zhen ;

Hernandez, Sairy ;

Liu, Juan ;

Huang, Chen ;

Mulla, Sohail ;

Wang, Yulei ;

Lim, Ho Yeong ;

Zhu, Andrew X. ;

Cheng, Ann-Lii .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) :1894-1905

[6] The efficacy and safety of Apatinib combined with TACE in the treatment of hepatocellular carcinoma: a meta-analysis [J].

Gong, Anan ;

Li, Xiaofei .

WORLD JOURNAL OF SURGICAL ONCOLOGY, 2022, 20 (01)

[7] Transarterial chemoembolization combined with camrelizumab for recurrent hepatocellular carcinoma [J].

Guo, Yusheng ;

Ren, Yanqiao ;

Chen, Lei ;

Sun, Tao ;

Zhang, Weihua ;

Sun, Bo ;

Zhu, Licheng ;

Xiong, Fu ;

Zheng, Chuansheng .

BMC CANCER, 2022, 22 (01)

[8] Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions [J].

Hilmi, Marc ;

Neuzillet, Cindy ;

Calderaro, Julien ;

Lafdil, Fouad ;

Pawlotsky, Jean-Michel ;

Rousseau, Benoit .

JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01)

[9] Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination [J].

Ju, Shuguang ;

Zhou, Chen ;

Hu, Junwen ;

Wang, Yingliang ;

Wang, Chaoyang ;

Liu, Jiacheng ;

Yang, Chongtu ;

Huang, Songjiang ;

Li, Tongqiang ;

Chen, Yang ;

Bai, Yaowei ;

Yao, Wei ;

Xiong, Bin .